AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

1. (**Previously Presented**) Compounds of Formula (I)



(I)

wherein

A is a group of the formula $-C(CH_3)=CHR^5$ or $-CH=CHR^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group,

U is hydrogen, halogen, C_1-C_4 alkyl, C_3-C_4-cycloalkyl, C_1-C_4 heteroalkyl-,-trifluromethyl or COOH,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R^1 is a C_1-C_4-alkyl-, a C_2-C_4-alkenyl-, a C_2-C_4-alkinyl- or a C_3-C_4-cycloalkyl-group,

V-W is a group of formula CH_2CH or CH=C,

X is oxygen or a group of the formula NR^2, wherein R^2 is hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, or C_1-C_4 heteroalkyl,
and

R^3 and R^4 independently from each other represent hydrogen, C_1-C_4-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

2. (**Canceled**)

3. (**Original**) Compounds according to claim 1, wherein A is a group of formula (II) or (III)



(II)



(III)

wherein Q is sulphur, oxygen or NR^7, wherein R^7 is hydrogen, C_1-C_4 alkyl or C_1-C_4 heteroalkyl, z is Nitrogen or CH and R^6 is OR^8, NHR^8, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkinyl or C_1-C_6 heteroalkyl, wherein R^8 is hydrogen, C_1-C_4 alkyl or C_1-C_4 heteroalkyl.

4. (**Previously Presented**) Compounds according to claim 1, wherein X is oxygen or NH.

5. (**Previously Presented**) Compounds according to claim 1, wherein R^1 is methyl or ethyl.

6. **(Previously Presented)** Compounds according to claim 1, wherein R^3 and R^4 are methyl groups.

7. **(Previously Presented)** Compounds according to claim 1, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.

8. **(Previously Presented)** Compounds according to claim 1, wherein G-E is selected from the following groups:



9. **(Previously Presented)** Compounds according to claim 1, wherein V-W is CH_2CH.

10. **(Previously Presented)** Pharmaceutical compositions containing a compound, a pharmacologically acceptable salt, a solvate or a hydrate according to claim 1 or a prodrug of the compound, the salt, the solvate and/or the hydrate and optionally one of more carriers and/or one or more adjuvants and/or one or more diluents.

11. **(Previously Presented)** Method of treating a disease selected from the group consisting of breast, ovarian, lung and prostate cancer through administering a pharmaceutically effective amount of a compound or a pharmaceutical composition according to claim 1.

12. **(Canceled)**

13. **(Currently Amended)** Compounds of formula ~~(IVa), (IVb),~~ (Va) and (Vb),



wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. (**Currently Amended**) A process for preparing a compound of formula (I), comprising reacting ~~Use of~~ a compound according to claim 13 ~~for the synthesis of a compound of formula (I b).~~ by

a) removing any protecting groups on the acid and allyl alcohol;

b) lactonizing the hydroxy acid;

c) removing any protecting groups on the remaining alcohols;

d) reducing the disubstituted double bond, if present; and

e) oxidizing the sulfur atom at the 5-position to a sulfoxide.